J Psychiatr Res (1997) 31:14956
Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms
Stack protocol: BPC-157: 250 to 500 mcg subcutaneous, once or twice a day Inject near the injury when you can reach it TB-500: 2 to 2.5 mg subcutaneous, twice a week (loading phase) Inject away from the injury, lower abdomen or outer thigh works fine 2 mg once a week (maintenance phase) Both run at the same time through the loading phase
Co-administration of Cagrilintide and Semaglutide in Adults with Overweight or Obesity: A Phase 2 Trial
Deficiency of vitamin B12 can result in neurologic, cognitive, and hematologic manifestations, most notably peripheral neuropathy, cognitive impairment, and macrocytic anemia
